Active HealthTree Research Projects
You can find all open HealthTree research projects in HealthTree Cure Hub
3-Year Bispecific Antibody Study
The multiple myeloma medical community is now able to provide bispecific antibody therapy to patients. This is a major study initiative that will be open to patients receiving bispecific antibodies, and will be open for enrollment for a minimum of 3 years. The study consists of 8 surveys designed to gather information about various aspects of the patient experience with bispecific antibodies, ranging from initial awareness to quality of life after at least four months of treatment. The surveys cover topics such as treatment decision-making, side effects, outcomes, caregiver involvement, financial aspects, and quality of life.
Because there are now three FDA approved bispecific antibodies with more coming in clinical development, this is critical information doctors need to know to correctly prescribe this therapy to myeloma patients.
Personalizing Treatment Strategies Based on Multiple Myeloma Patient Genetics at Diagnosis
The University of Miami team is creating a computational Individualized Risk model for Myeloma (IRMMa) to help newly diagnosed patients understand their best treatment path based on their genetics at diagnosis. They do this by performing genetic testing on bone marrow biopsy slides performed at diagnoses. They then review how patients were treated to identify which myeloma therapies and combinations are most effective. They have completed this testing on many University of Miami patients and need more patients to participate to build a model that is statistically accurate. Multiple myeloma is a single disease and when patients are broken into subcategories, data from thousands of patients are needed to accurately predict outcomes.
Understanding Stem Cell Transplant Patient Experiences
This survey was designed by Myeloma Coaches and aims to better understand the patient experience during the stem cell transplant process. For example, were side effects different than expected, was the predicted recovery time accurate, what was the decision process to undergo a transplant, or why did patients decide not to undergo a transplant? This survey is dedicated to Myeloma Coach Susan Thaul, a myeloma patient, scientist, Myeloma Coach and epidemiologist (passed away May 2023), who was instrumental in its creation.
Sexual Health of Blood Cancer Patients: Helping the Birds and the Bees!
This observational study aims to explore the impact of treatments on blood cancer patients' sexual health and investigate preferences and experiences in discussing this topic with their care team.
Physical Activity and Barriers to Movement
This survey aims to identify physical activity levels and barriers to exercise among blood cancer patients.
Eye Health in MGUS, Smoldering and Multiple Myeloma Patients
Myeloma experts Rahul Banerjee, MD and Andrew Cowan, MD of the Fred Hutchinton are interested in knowing if your eye health has been impacted by precursor conditions or multiple myeloma, or drugs used to treat these conditions. The researchers are interested in gathering information about eye health, medications that might affect eye health and quality of life among patients with these conditions.
You can find all open HealthTree research projects in HealthTree Cure Hub
3-Year Bispecific Antibody Study
The multiple myeloma medical community is now able to provide bispecific antibody therapy to patients. This is a major study initiative that will be open to patients receiving bispecific antibodies, and will be open for enrollment for a minimum of 3 years. The study consists of 8 surveys designed to gather information about various aspects of the patient experience with bispecific antibodies, ranging from initial awareness to quality of life after at least four months of treatment. The surveys cover topics such as treatment decision-making, side effects, outcomes, caregiver involvement, financial aspects, and quality of life.
Because there are now three FDA approved bispecific antibodies with more coming in clinical development, this is critical information doctors need to know to correctly prescribe this therapy to myeloma patients.
Personalizing Treatment Strategies Based on Multiple Myeloma Patient Genetics at Diagnosis
The University of Miami team is creating a computational Individualized Risk model for Myeloma (IRMMa) to help newly diagnosed patients understand their best treatment path based on their genetics at diagnosis. They do this by performing genetic testing on bone marrow biopsy slides performed at diagnoses. They then review how patients were treated to identify which myeloma therapies and combinations are most effective. They have completed this testing on many University of Miami patients and need more patients to participate to build a model that is statistically accurate. Multiple myeloma is a single disease and when patients are broken into subcategories, data from thousands of patients are needed to accurately predict outcomes.
Understanding Stem Cell Transplant Patient Experiences
This survey was designed by Myeloma Coaches and aims to better understand the patient experience during the stem cell transplant process. For example, were side effects different than expected, was the predicted recovery time accurate, what was the decision process to undergo a transplant, or why did patients decide not to undergo a transplant? This survey is dedicated to Myeloma Coach Susan Thaul, a myeloma patient, scientist, Myeloma Coach and epidemiologist (passed away May 2023), who was instrumental in its creation.
Sexual Health of Blood Cancer Patients: Helping the Birds and the Bees!
This observational study aims to explore the impact of treatments on blood cancer patients' sexual health and investigate preferences and experiences in discussing this topic with their care team.
Physical Activity and Barriers to Movement
This survey aims to identify physical activity levels and barriers to exercise among blood cancer patients.
Eye Health in MGUS, Smoldering and Multiple Myeloma Patients
Myeloma experts Rahul Banerjee, MD and Andrew Cowan, MD of the Fred Hutchinton are interested in knowing if your eye health has been impacted by precursor conditions or multiple myeloma, or drugs used to treat these conditions. The researchers are interested in gathering information about eye health, medications that might affect eye health and quality of life among patients with these conditions.
Upcoming Events
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.